Hologic Completes $17.3 Billion Go-Private Acquisition, Delists from Nasdaq

summarizeSummary

Hologic completed its $17.3 billion go-private acquisition by Blackstone and TPG, leading to its delisting from Nasdaq, a full board and CEO change, and significant debt repayment.

check_boxKey Events

• Merger Completion

  Hologic finalized its acquisition by Blackstone and TPG, becoming a private company. Public shareholders received $76.00 per share in cash plus a CVR for up to $3.00 per share.

• Delisting and Deregistration

  The company's common stock has ceased trading and will be delisted from Nasdaq, with deregistration from the SEC to follow.

• Leadership Overhaul

  Stephen P. MacMillan resigned as CEO, and all prior directors departed. José (Joe) E. Almeida was appointed as the new Chief Executive Officer and director.

• Debt Restructuring

  Hologic repaid $1.35 billion in outstanding senior notes (2028 and 2029 series) as part of the transaction.

auto_awesomeAnalysis

Hologic has finalized its acquisition by Blackstone and TPG, transitioning into a private entity. This transaction provides public shareholders with $76.00 per share in cash plus a contingent value right (CVR) for up to an additional $3.00 per share, tied to future performance of the Breast Health business. The completion of this merger, which sees the company trading near its 52-week high, results in the delisting of Hologic's common stock from Nasdaq and a complete change in its board and executive leadership, with Joe Almeida appointed as the new CEO. Additionally, the company repaid $1.35 billion in outstanding senior notes, significantly restructuring its debt under the new ownership.